Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2022 Jun 7;10(6):e004291corr1. doi: 10.1136/jitc-2021-004291corr1

Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

PMCID: PMC9174757  PMID: 35672079

Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J ImmunoTher Cancer 2022;10:e004291.

This article has been corrected since it was first published online. 'Shanghai Chest Hospital' has been added before 'Shanghai Jiao Tong University' in the affiliations of the relevant authors.


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES